AMPE vs. ATHX, SXTC, CALA, APVO, ADTX, BLPH, EVFM, SBFM, SPRC, and EVLO
Should you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Athersys (ATHX), China SXT Pharmaceuticals (SXTC), Calithera Biosciences (CALA), Aptevo Therapeutics (APVO), Aditxt (ADTX), Bellerophon Therapeutics (BLPH), Evofem Biosciences (EVFM), Sunshine Biopharma (SBFM), SciSparc (SPRC), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical preparations" industry.
Athersys (NASDAQ:ATHX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.
19.4% of Athersys shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Athersys received 365 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 60.53% of users gave Athersys an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote.
Ampio Pharmaceuticals has lower revenue, but higher earnings than Athersys. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.
Ampio Pharmaceuticals' return on equity of 0.00% beat Athersys' return on equity.
In the previous week, Athersys had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 1 mentions for Athersys and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Athersys'average media sentiment score.
Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500.
Summary
Athersys beats Ampio Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
Get Ampio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ampio Pharmaceuticals Competitors List
Related Companies and Tools
